

# Inhaled Fluticasone in Wheezy Infants

<b>Submission date</b> 07/11/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 28/11/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 07/01/2008	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Clare Murray

**Contact details**  
North West Lung Research Centre  
Wythenshawe Hospital  
Southmoor Road  
Manchester  
United Kingdom  
M23 9LT  
+44 (0)161 291 4199  
cmurray@fs1.with.man.ac.uk

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

**Secondary identifying numbers**  
N/A

## Study information

## Scientific Title

### Acronym

IFWIN

### Study objectives

1. Can the early introduction of inhaled corticosteroids (ICS) prevent the progressive fall in lung function seen in asthmatics?
2. Can early introduction of inhaled corticosteroids in children with asthma modify the natural history of the disease or prevent recurrence of asthma later in life?
3. Does treatment with ICS reduce symptoms in non-asthmatic wheezy children and improve their lung function at age 6 years?
4. Do inhaled corticosteroids improve the quality of life of families with wheezing children?
5. Is continuous treatment with ICS at this dose in young children associated with any local or systemic side effects?

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

ERP/97/023, 21st April 1997

### Study design

A randomized double blind placebo controlled study investigating the effects of early intervention with low dose inhaled corticosteroids (fluticasone propionate) in young children with wheeze

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Not specified

### Study type(s)

Treatment

### Participant information sheet

### Health condition(s) or problem(s) studied

Asthma in children

### Interventions

Low dose inhaled corticosteroids (fluticasone propionate) versus placebo

### Intervention Type

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Fluticasone propionate

**Primary outcome measure**

1. Occurrence of asthma at age 5 and 6
2. Lung function at age 5
3. Non-specific bronchial hyper-reactivity at age 5
4. Number of courses and total dose of add-on fluticasone propionate required

**Secondary outcome measures**

1. Rescue and added asthma medication
2. Number of exacerbations
3. Safety parameters length/height, weight
4. Symptom scores
5. Adrenal function

**Overall study start date**

01/05/1997

**Completion date**

31/03/2003

**Eligibility****Key inclusion criteria**

1. Children aged 6 months to 4 years
2. Two episodes of doctor verified wheeze or one episode continuous for more than 4 weeks

**Participant type(s)**

Patient

**Age group**

Child

**Lower age limit**

6 Months

**Upper age limit**

4 Years

**Sex**

Both

**Target number of participants**

200

**Key exclusion criteria**

1. Pre-term less than 34 weeks gestation
2. Neonatal lung disease or other lung disease
3. Other chronic disease
4. Children already or previously used an inhaled corticosteroid
5. Children who cannot use the spacer device

**Date of first enrolment**

01/05/1997

**Date of final enrolment**

31/03/2003

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

North West Lung Research Centre

Manchester

United Kingdom

M23 9LT

## Sponsor information

**Organisation**

Wythenshawe Hospital (UK)

**Sponsor details**

Andrew Maines

R&D Directorate

ERC Building

Wythenshawe Hospital

Southmoor Road

Manchester

England

United Kingdom

M23 9LT

+44 (0)161 291 5775

amaines@fs1.with.man.ac.uk

**Sponsor type**

Hospital/treatment centre

ROR

<https://ror.org/05vpsdj37>

## Funder(s)

### Funder type

Industry

### Funder Name

GlaxoSmithKline (UK)

### Alternative Name(s)

GlaxoSmithKline plc., GSK plc., GSK

### Funding Body Type

Government organisation

### Funding Body Subtype

For-profit companies (industry)

### Location

United Kingdom

## Results and Publications

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Results	26/08/2006		Yes	No